Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2015

View Archived Issues

Principia evaluating PRN-1371 in phase I trial for advanced solid tumors

Effector Therapeutics initiates trial of Mnk1/2 inhibitor eFT-508 in patients with solid tumors

FXR agonist EYP-001 shows activity against HBV replication

EMA accepts Helsinn's MAA for anamorelin in cancer-related cachexia

New CD137/HER2 bispecific Anticalin-based protein shows promising antitumoral activity

Fibroblast activation inhibitor preserves cardiac function after heart failure in animal model

Sprint Bioscience collaborates with Gothenburg University on diabetes program

University of Colorado patents HDAC/TTK inhibitors

Takeda and Teva to form Japanese generic pharmaceuticals venture

Peloton Therapeutics disclosed ACSS2 inhibitors

AbbVie announces V1bR ligands

X-Rx reports autotaxin inhibitors

Array BioPharma patents Trk-A inhibitor

Bayer Schering Pharma divulges sGC activators

Novartis discloses TLR7 agonists

FDA issues complete response letter for Opdivo

EC grants marketing authorization for Numient in the treatment of Parkinson's disease

Oncoceutics starts phase I trial of ONC-201 in solid tumors and multiple myeloma

Rottapharm's antibody CRB-0017 prevents joint damage in animal models of osteoarthritis

PCSK9 vaccine reduces cholesterol and triglyceride levels in mice and monkeys

Gene therapy that restores copper metabolism in model of Wilson disease granted E.U. orphan status

Novel biomarkers of lupus nephritis activity identified through urinary proteomics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...